PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

Phase 2

Completed

Conditions: MSS
RAS-mutant Colorectal Cancer

Interventions: Drug: binimetinib
Drug: nivolumab
Drug: ipilimumab

First Posted Date: 2017-09-01

Last Posted Date: 2022-01-04

Lead Sponsor: Pfizer

Target Recruit Count: 75

Registration Number: NCT03271047

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Siteman Cancer Center - South County, Saint Louis, Missouri, United States
🇪🇸
Hospital Universitario Vall d'Hebrón - PPDS, Barcelona, Spain

and more 46 locations

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: PF-06863135 + pomalidomide
Drug: PF-06863135 monotherapy IV or SC
Drug: PF-06863135 + dexamethasone
Drug: PF-06863135 + lenalidomide

First Posted Date: 2017-08-31

Last Posted Date: 2025-03-18

Lead Sponsor: Pfizer

Target Recruit Count: 101

Registration Number: NCT03269136

Locations: 🇺🇸
UChicago Medicine - River East, Chicago, Illinois, United States
🇺🇸
UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Hospital), La Jolla, California, United States
🇺🇸
UCSD Medical Center - Vista, Vista, California, United States

and more 34 locations

Open Label Safety Study in Acute Treatment of Migraine

Phase 2

Completed

Conditions: Migraine, With or Without Aura

Interventions: Drug: Rimegepant

First Posted Date: 2017-08-30

Last Posted Date: 2023-02-16

Lead Sponsor: Pfizer

Target Recruit Count: 3019

Registration Number: NCT03266588

Locations: 🇺🇸
FutureSearch Trials of Neurology, LP, Dallas, Texas, United States
🇺🇸
Woodland Research Northwest, LLC, Rogers, Arkansas, United States
🇺🇸
Clinical Neuroscience Solutions, Inc, Memphis, Tennessee, United States

and more 82 locations

A Study Comparing Amounts of 2 Different Forms of Tafamidis (PF-6291826) in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: tafamidis

First Posted Date: 2017-08-30

Last Posted Date: 2018-05-14

Lead Sponsor: Pfizer

Target Recruit Count: 30

Registration Number: NCT03266705

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis

Phase 1

Completed

Conditions: Atopic Dermatitis
Healthy

Interventions: Drug: Crisaborole ointment 2%
Drug: Vehicle

First Posted Date: 2017-08-24

Last Posted Date: 2019-03-01

Lead Sponsor: Pfizer

Target Recruit Count: 32

Registration Number: NCT03260595

Locations: 🇯🇵
Medical Corporation Heishinkai OPHAC Hospital, Osaka-shi, Osaka, Japan

A Study to Learn About the Effects of Multiple Doses of Sisunatovir on People With Respiratory Syncytial Virus (RSV) Infection

Phase 2

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Drug: Placebo
Drug: RV521

First Posted Date: 2017-08-23

Last Posted Date: 2025-02-05

Lead Sponsor: Pfizer

Target Recruit Count: 66

Registration Number: NCT03258502

Locations: 🇬🇧
hVIVO Services Ltd, London, United Kingdom

6-week Safety and PD Study in Adults With NAFLD

Phase 2

Completed

Conditions: Non-alcoholic Fatty Liver Disease

Interventions: Drug: PF-06835919 High Dose
Drug: Placebo
Drug: PF-06835919 Low Dose

First Posted Date: 2017-08-22

Last Posted Date: 2019-04-04

Lead Sponsor: Pfizer

Target Recruit Count: 53

Registration Number: NCT03256526

Locations: 🇺🇸
WR-ClinSearch LLC, Chattanooga, Tennessee, United States
🇺🇸
Stand-Up MRI of Miami, Miami, Florida, United States
🇺🇸
Sterling Research Group, Ltd., Cincinnati, Ohio, United States

and more 5 locations

Absorption, Metabolism, Excretion and Absolute Bioavailability

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Absolute Bioavailability
Drug: PF-04965842

First Posted Date: 2017-08-15

Last Posted Date: 2017-12-21

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT03250039

Locations: 🇳🇱
PRA Health Sciences, Groningen, Netherlands

Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

Phase 2

Completed

Conditions: Nonalcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis

Interventions: Drug: Placebo
Drug: PF-05221304

First Posted Date: 2017-08-14

Last Posted Date: 2020-12-09

Lead Sponsor: Pfizer

Target Recruit Count: 305

Registration Number: NCT03248882

Locations: 🇨🇦
Discovery Clinical Services Ltd., Victoria, British Columbia, Canada
🇺🇸
South Denver Gastroenterology, P.C., Englewood, Colorado, United States
🇺🇸
ClinSearch, Chattanooga, Tennessee, United States

and more 134 locations

Understanding Hemophilia A and B Drug Dosage Administration Patterns

Terminated

Conditions: Hemophilia A
Hemophilia B

Interventions: Drug: Hemophilia B standard half-life
Drug: Hemophilia A standard half-life
Drug: Hemophilia B extended half-life
Drug: Hemophilia A extended half-life

First Posted Date: 2017-08-14

Last Posted Date: 2019-05-20

Lead Sponsor: Pfizer

Target Recruit Count: 11

Registration Number: NCT03248141

Locations: 🇺🇸
University of Florida College of Medicine, Gainesville, Florida, United States
🇺🇸
Alliance for Childhood Diseases, dba Hemophilia Treatment Center of Nevada, Las Vegas, Nevada, United States
🇺🇸
Cook Children's Medical Center, Fort Worth, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy